Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Non-Current Deffered Revenue (2016 - 2026)

Standard Biotools has reported Non-Current Deffered Revenue over the past 16 years, most recently at $3.5 million for Q4 2025.

  • Quarterly Non-Current Deffered Revenue fell 89.28% to $3.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.5 million through Dec 2025, down 89.28% year-over-year, with the annual reading at $3.5 million for FY2025, 89.28% down from the prior year.
  • Non-Current Deffered Revenue was $3.5 million for Q4 2025 at Standard Biotools, up from $2.4 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $33.9 million in Q1 2024 and troughed at $2.4 million in Q3 2025.
  • The 5-year median for Non-Current Deffered Revenue is $5.4 million (2022), against an average of $11.7 million.
  • Year-over-year, Non-Current Deffered Revenue soared 840.76% in 2024 and then plummeted 92.76% in 2025.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $6.0 million in 2021, then plummeted by 36.04% to $3.8 million in 2022, then decreased by 7.76% to $3.5 million in 2023, then skyrocketed by 828.24% to $32.7 million in 2024, then plummeted by 89.28% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Non-Current Deffered Revenue are $3.5 million (Q4 2025), $2.4 million (Q3 2025), and $2.8 million (Q2 2025).